

Decitabine for untreated acute myeloid leukaemia (terminated appraisal)

Technology appraisal guidance

Published: 5 December 2018

[nice.org.uk/guidance/ta548](https://www.nice.org.uk/guidance/ta548)

Contents

Advice	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was received from Janssen. The company has confirmed that it does not intend to make a submission because there is unlikely to be sufficient evidence that decitabine is a cost-effective use of NHS resources in this population.

Information

If NHS organisations wish to consider decitabine for untreated acute myeloid leukaemia, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-3185-9

Accreditation

